Bruker Corporation (NASDAQ:BRKR) Stock Has Consensus Target Price of $58.57

Bruker Corporation (NASDAQ:BRKR) has earned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $59.79.

Several research firms have commented on BRKR. Citigroup lowered their target price on shares of Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research note on Wednesday, August 5th. Stifel Nicolaus set a $50.00 price target on Bruker in a report on Wednesday, August 5th. TD Cowen increased their price target on Bruker from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday. The Goldman Sachs Group raised Bruker from a “strong sell” rating to a “strong-buy” rating in a research note on Monday, September 21st. Finally, UBS Group initiated coverage on Bruker in a report on Wednesday, September 9th. They set a “neutral” rating and a $65.00 price objective on the stock.

Bruker Stock Performance

Shares of NASDAQ BRKR opened at $56.19 on Friday. The company has a market cap of $8.56 billion, a PE ratio of -80.27, a price-to-earnings-growth ratio of 1.72 and a beta of 1.22. Bruker has a 12 month low of $32.37 and a 12 month high of $66.98. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The company has a 50-day simple moving average of $58.59 and a 200-day simple moving average of $53.04.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts anticipate that Bruker will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Monday, September 21st were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date was Monday, September 21st. Bruker’s dividend payout ratio is presently -28.57%.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the sale, the vice president directly owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 27.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BRKR. Pallas Capital Advisors LLC purchased a new position in Bruker in the second quarter valued at about $570,746,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Bruker in the second quarter worth about $169,899,000. Franklin Resources Inc. boosted its position in shares of Bruker by 317.7% in the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after buying an additional 1,756,460 shares during the period. Primecap Management Co. CA acquired a new stake in shares of Bruker in the second quarter valued at about $53,145,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Bruker in the second quarter valued at about $44,839,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company’s portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.